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Abstract 
 
Background. Mutations in SCN1A can cause Genetic Epilepsy with Febrile Seizures Plus (GEFS+, 
inherited missense mutations) or Dravet syndrome (DS, de novo mutations of all types). Although the 
mutational spectra are distinct, these disorders share major features and 10% of DS patients have an 
inherited SCN1A mutation.  
Objectives and patients. We studied 19 selected families with at least one DS patients to describe the 
mechanisms accounting for inherited SCN1A mutations in DS. The mutation identified in the DS probands 
was searched in available parents and relatives and quantified in the blood cells of the transmitting parent 
using quantitative allele-specific assays. 
Results. Mosaicism in the blood cells of the transmitting parent was demonstrated in 12 cases and 
suspected in another case. The proportion of mutated allele in the blood varied from 0.04% to 85%. In the 
6 remaining families, six novel missense mutations were associated with autosomal dominant variable 
GEFS+ phenotypes including DS as the more severe clinical picture.  
Conclusion. Our results indicate that mosaicism is found in at least 7% of families with at least one DS 
patient and that it accounts for 68 % (13/19) of inherited mutations associated with DS. On the contrary, in 
the remaining cases (6/19, 32%), the patients were part of multiplex GEFS+ families and seemed to 
represent the extreme end of the GEFS+ clinical spectrum. In this latter case, additional genetic or 
environmental factors likely modulate the severity of the expression of the mutation. 
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Dravet Syndrome (DS), previously known as severe myoclonic epilepsy in infancy (SMEI MIM# 607208), 
is an epileptic encephalopathy with typical clinical features including onset of seizures before one year, 
generalized or hemiclonic seizures that are often prolonged and typically triggered by fever, and later 
apparition of polymorphic afebrile seizures that remain resistant to anti-epileptic treatments over time. The 
psychomotor development of the child, originally normal, becomes progressively delayed from age 2 and 
ataxia frequently develops [1, 2]. 
Genetic Epilepsy with Febrile Seizures Plus (previously described as Generalized Epilepsy with Febrile 
seizures plus or GEFS+, MIM# 604233) is a variable autosomal dominant epileptic condition that also 
associates febrile and afebrile seizures. Affected family members present with phenotypes ranging from 
isolated febrile seizures to various idiopathic generalized epilepsy subtypes (epilepsy with grand mal 
seizures, childhood absence or juvenile myoclonic epilepsy) or can remain asymptomatic. The outcome is 
usually benign and patients are sensitive to classical anti-epileptic treatments. However, family members 
can occasionally experience focal seizures, be severely affected and/or pharmacoresistant, and even 
present with DS [3, 4, 5, 6]. 
Mutations in SCN1A, the gene encoding the neuronal sodium channel alpha I subunit (Nav1.1) were 
initially identified in GEFS+ families [7]. Shortly after, de novo SCN1A mutations were reported to be the 
major cause of DS, accounting for up to 80% of the patients [8, 9, 10, 11]. Missense mutations are 
exclusively found in GEFS+ whereas mutations associated with DS include all mutation types mutations 
as well as large rearrangements of the gene [10, 11, 12, 13, 14, 15]. De novo missense mutations found in 
DS patients are never found in GEFS+ families, suggesting that the pathophysiological mechanisms are 
distinct in these disorders. Mutational spectrum in DS is compatible with a complete loss of function of the 
mutated allele (haploinsufficiency) [16]. The functional consequences of mutations associated with 
GEFS+, probably a gain or a partial loss of function, remain more controversial so far [17, 18, 19, 20, 21, 
22]. Yet, DS and GEFS+ share major features, including sensitivity to seizures and polymorphous seizure 
types, and patients with DS have occasionally been reported in GEFS+ families, suggesting that DS could 
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be at the severe end of the GEFS+ spectrum [23, 24, 25, 26, 27, 28]. On the contrary, patients with DS 
sometimes have a parent or relative with a milder epileptic phenotype and mutations inherited from an 
asymptomatic or mildly affected parent are identified in 10% of the DS patients [10, 29, 30, 31, 32, 33]. In 
2006, we and others have shown that parental mosaicism can cause recurrent transmission of SCN1A 
mutations associated with DS [34, 35, 36, 37]. 
 
In this study, we investigated 19 families comprising at least one patient with DS in whom a SCN1A 
mutation was inherited. Our objectives were to estimate the frequency of parental mosaicism in a large 
cohort of DS patients and to determine whether other mechanisms could account for inherited SCN1A 
mutations in DS. 
 
Materials and Methods 
Patients, recruited in different French medical centres, were referred to our laboratory for molecular 
analysis of SCN1A [10]. We selected 19 index cases with DS who had an inherited SCN1A mutation 
based on molecular and/or familial arguments for further genetic investigations (Figure 1). Families 3, 4, 8, 
11 and 13 included sib pairs with DS from healthy parents whereas families 1, 2, 5, 6, 7, 9, 12, 14, 15, 16, 
17, 18 and 19 included a single patient with DS. In family 10, an elder child was deceased prematurely 
after a status epilepticus episode without a confirmed diagnosis of DS. Families 1, 5, 12, 14, 15, 16, 17, 18 
and 19 also included one or more affected relative(s) with milder epilepsy compatible with GEFS+ 
condition (Figure 1A and 1B). In family 2 one parent had a single TCGS. Clinical features and mutations 
of families 3 and 11 were already reported [35]. Informed written consent was obtained from each 
individual before or his/her legal guardian blood sampling. This study was approved by the ethical 
committee (CCPPRB of Pitié-Salpêtrière Hospital, Paris, n°69-03, 25/9/2003).  
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SCN1A, SCN8A and SCN9A analyses 
SCN1A was screened by direct sequencing and MLPA (multiplex ligation-dependent probe amplification) 
as previously described [10]. Mutations found in DS patients were searched for by direct sequencing of the 
corresponding exon in both parents; in the case of de novo mutations, seven highly polymorphic 
microsatellite markers (AFMa081we1, D2S2157, D2S124, D2S2363, D2S1395, D2S1379, AFMb362wd1) 
were used to confirm the pedigree structure. Four of these microsatellite markers at the 2q24.3 
(SCN1A/SCN9A) locus (AFMa081we1, D2S124, D2S1395, and AFMb362wd1) and two microsatellite 
markers at the 12q13.13 (SCN8A) locus (D12S1629 and D12S1651) were genotyped in family members 
to establish haplotypes and follow segregation of the corresponding alleles in the families. PCR products 
mixed with the GENESCANTM 400HD ROX standard (Applied Biosystems) were run on an ABI 3730 
automated sequencer (Applied Biosystems). Genotypes were analyzed with GeneMapper 3.5 software 
(Applied Biosystems). 
Quantitative allele-specific PCR 
Principle and experimental conditions for the allele-specific real time PCR assays, derived from the 
mismatch amplification mutation assay (TaqMAMA) were previously described [35]. Primer pairs specific 
for the mutations found in families 1-12, 14 and 15 were designed using PrimerExpress 1.5 (primer 
sequences are available on request). Specific and quantitative amplification using at least one primer pair 
was ensured using serial dilutions of DNA from the DS patient of each family in DNA from a control 
individual in which 75%, 50%, 25%, or 12.5% of the DNA is from the patient. All real-time PCR 
experiments were performed using 100 ng of genomic DNA, 0.4 µM of each primer and 12.5 µl of Sybr 
Green PCR master mix (Applied Biosystems) in a total volume of 25 µl. The RNAse P (RNAse P control 
assay from Applied Biosystems) was used as the reference amplicon. Each sample was run in triplicate on 
an ABI PRISM 7700 Detection system (Applied Biosystems) and three different experiments were used 
for final quantification. Relative ratios were calculated using the formula r = 2–ΔΔCt 
with ΔΔCt = (Ct Mutation - Ct RNAseP) ind tested – (Ct Mutation – Ct RNAseP) ind ref 
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Results 
Since 2003, we have screened a large series of 421 unrelated patients with DS for mutations in SCN1A 
(333 patients were previously reported [10]). At the time of this study, 319 patients (75%) had a mutation 
in SCN1A. Analysis of both parents was possible for 177 patients and the mutation was de novo in 
159/177 cases (89%). In the 19 remaining cases, the mutation was inherited from one parent (Figure1, 
Table 1A). Inherited mutations included 4 nonsense mutations (p.Arg542X, p.Arg712X, p.Arg1912X and 
p.Arg580X), 3 mutations altering the splice sites (c.1377+1 G>A, c.602+1 G>A and c.965-2 A>C), 2 
exonic deletions of one base pair (c.3878delA and c.5493delT), one whole gene deletion and 9 missense 
mutations (p.Ile124Asn, p.Asn191Tyr, p.Ile1782Met, p.Thr875Lys, p.Asn1367Lys, p.Leu1514Ser, 
p.Arg1648His, p.Thr1658Met and p.Met1664Lys). All mutations were absent from 180 Caucasian healthy 
controls. 
The mutations were detectable in DNA extracted from the blood cells of the parent using direct sequencing 
in 15/19 cases. However, the amount of the mutated allele in the transmitting parent appeared lower than 
that of the affected child in 9 cases (families 1-9, Suppl. Figure1A), suggesting somatic mosaicism. In 3 
families, the mutation was undetectable using direct sequencing in both parents but had been transmitted to 
two affected siblings (families 10-12), indicating germinal mosaicism. Finally, only the mother was 
available for genetic analysis in family 13 (whole gene deletion in two brothers) but she did not have the 
deletion.  
Mosaicism in the parent of families 1-12 was confirmed using quantitative allele-specific real-time assays 
(Table 1A). The proportion of each mutation in the blood cells varied from 85% (family 1) to 0.04% 
(family 12). Although the mutation could not be detected using standard methods in families 10-12, the 
allele-specific assays allowed a specific amplification of the mutation from blood cells’ DNA of the parent 
in all three cases. In family 12, the quantity of mutation detected was very low but significant positive 
results were obtained for the mother (0.0392 ± 0.00643) compared to the father (0.00677 ± 0.00070, 
equivalent to that found in control individuals), indicating that the mutation was present at a very low level 
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in the blood cells of the mother. Likewise, in family 11, the allele-specific assay previously allowed a 
specific amplification from the blood cells’ DNA of the father although direct sequencing failed to reveal 
the mutation [35]. The amount of mutation was previously estimated to 6% in the blood but we showed 
that the mutation was present at a higher proportion in the sperm (24% ±11, not shown). Together, these 
results confirmed that the transmitting parents carried the mutation at the mosaic state in their blood cells 
and/or in their germ cells in the 12 families (1-12). The mutation was inherited from the mother in 6 cases 
and from the father in the 6 others. Analysis of microsatellite markers in the SCN1A gene revealed that the 
whole gene deletion in family 13 originated from the father allele who was unavailable for genetic 
analyses (Suppl. Figure 2A). He was reported unaffected and mosaicism was therefore hypothesized in this 
family.  
Contrary to families 1-12, the amount of the mutated allele in families 14-19 was identical in DS patients 
and their transmitting parent (Suppl. Figure 1B). In these 6 families, mutations were all of missense type 
and family histories were suggestive of autosomal dominant GEFS+ condition. In 2 families (16 and 19), 
the Leu1514Ser and Met1664Lys mutations were inherited over three or more generations, excluding the 
possibility of mosaicism in the transmitting parent (Figure 1B and Suppl. Figure 1B). In family 18, the 
Thr1658Met mutation was inherited from the asymptomatic mother who had affected brother and sister, 
suggesting that this mutation was also inherited over three generations, although none of them were 
available for genetic analyses. The Arg1648His mutation (family 17), was previously reported to cause 
GEFS+ in a large family [7]. The Thr875Lys mutation (family 14) affects the same amino-acid than the 
Thr875Met mutation described in another GEFS+ family [7] and was associated with a mild epilepsy in 
the sister’s proband. In families 14 and 15, however, the mutation arose de novo in the transmitting fathers. 
The paternal grand-parents did not have the Thr875Lys mutation in family 14 (Suppl. Figure 1B). In 
family 15, analysis of microsatellite markers at the SCN1A locus revealed that the same haplotype was 
present with the Asn1367Lys mutation in the affected father and his daughter with DS, and without the 
mutation in his two healthy sisters (Suppl. Figure 1B and 2B). These results indicate that the mutation 
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occurred de novo in the father or in one of his unavailable parents (Suppl. Figure 2B). We used allele-
specific PCR assays to quantify the mutation in the blood of the fathers in these 2 families. The amount of 
mutated allele was similar in the fathers and in their affected children (not shown), supporting the 
hypothesis that this mutation was associated with GEFS+ phenotypes although somatic mosaicism in other 
tissues could not be totally excluded. 
Interestingly, the mosaic parent had had seizures in 6 families (1, 2, 5, 7, 8 and 9, Supp. Table 2). In 
family 1, the father had febrile seizures before age six and presented since early childhood with afebrile 
generalized tonic seizures and frequent myoclonic jerks. His epilepsy was less active when treated with 
AEDs but he was still on therapy at age 52. He presented with a slight mental delay and had scholar 
difficulties since the first elementary years. In family 2, the father also presented with a few febrile 
seizures before age 6 and had a unique generalized tonic-clonic seizure at age 25. However, he had a good 
social insertion and normal cognitive abilities. In family 5, the mother was reported to have seizures since 
adolescence and was treated by carbamazepin and vigabatrin. Seizures were reported as focal temporal and 
GTC. She had a suspicion of left hippocampal sclerosis on MRI at age 28 and she was on waiting list for 
presurgical evaluation. She had a slight mental delay and a difficult social insertion, also due to her 
frequent seizures and for behavioural disturbances. The father of family 7 was intoxicated with carbon 
monoxide during infancy. He developed some GTCS during his childhood that stopped at the adolescence 
period. He was free of seizures without medication since this period. In family 8, the mother had seizures 
from the age of 11 months that remained untreated. She had no seizures between age 8 and 20 years. At 
the age of 20, seizures resumed and she was treated by phenobarbital. Treatment cessation led to the 
recurrence of the epilepsy. When seen at the age of 53, she was treated with sodium valproate and 
lamotrigine. In family 9, the father had no history of febrile seizures. He developed focal seizures at the 
age of 27, after a head trauma, but was free of seizures since he was treated with carbamazepine. It was 
therefore unclear whether the mutation was related to the development of seizures in this patient. 
If we exclude this latter case, the five affected mosaic parents have relatively high amounts of mutation in 
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their blood cells (85%; 65%, 50%, 45% and 43% respectively). Furthermore, the higher the amount of 
mutation was, the more severely the parent was affected. In contrast, mosaic parents of families 10-12, 
with the lowest amounts of mutations (18 to 0.04%) were all asymptomatic.  
In contrast to their mosaic parent, all mutated children but one had classical DS. In 6 families, the mutation 
was present in two siblings and the clinical features of both children were remarkably similar with the 
exception of family 12. However, some discrepancies were observed, regarding for example the age at 
onset, occurrence of myoclonic jerks and status epilepticus. Strikingly, in family 12, the brother of the 
proband had the same mutation than his sister with DS (Arg1580X) but did not have DS: he had prolonged 
febrile seizures between age 1 and age 2 but had been free of seizures without medication afterwards until 
age 14. At the age of 14, he developed afebrile generalized tonic-clonic seizures. Interestingly, this patient 
and his sister were genoidentical at the SCN1A locus (Suppl. Figure 3), indicating that the differences in 
phenotypes were not due to variants on the remaining normal SCN1A allele. 
Two genes, SCN8A and SCN9A encoding neuronal voltage-gated sodium channels paralogous to SCN1A, 
have been reported to be modifiers of DS [38, 39]. To investigate whether these genes could be responsible 
for the clinical differences observed in families 12, 14, 17 and 18, in which sib pairs were discordant, we 
genotyped 6 microsatellite markers at the SCN1A/SCN9A (2q24) and SCN8A (12q13) loci. In family 12, 
neither SCN9A (located near SCN1A) nor SCN8A could explain the moderate phenotype in the brother of 
the proband since they share the same genotypes at both loci. Likewise, in family 18, at least two 
discordant patients share the same genotype for each locus (Suppl. Figure 3).  These results indicated that 
SCN8A and SCN9A were not the modifier genes, at least in these families. 
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Discussion 
In this study, we have shown that mosaicism is the main event associated with inherited SCN1A mutations 
in DS patients (68%, 13/19 families). Parental mosaicism in DS is not a rare situation since it was found in 
at least 7% (13/177) of the families with a SCN1A mutation in our cohort [10]. When the level of somatic 
mosaicism is high, the parent can present with seizures, although he is less severely affected than his child 
who carry the mutation in all his cells. Nevertheless, mosaicism is not the only situation accounting for 
inherited mutations as DS can also be encountered in the context of GEFS+ families. In that case, SCN1A 
missense mutations segregating in the family are associated with a wide phenotypic variability, with DS at 
the severe end of the spectrum. Inherited mutations introducing a premature termination codon (i.e. 
nonsense, spice site mutations, mutations introducing frameshifts) were always associated with somatic 
mosaicism. It was thus hypothesized that the two brothers in family 13 had inherited the gene deletion 
from a mosaic father. On the contrary, the example of families 14 and 15 illustrates that it can be difficult 
to make a clear distinction between these two situations when confronted to missense mutations without 
clear evidence of mosaicism or GEFS+ context. Distinguishing mosaicism from de novo constitutional 
mutations or other situations is of particular concern in disorders that are frequently sporadic, such as DS, 
in order to give appropriate genetic counseling [40]. 
DS patients with inherited SCN1A mutations were periodically reported in the literature: the 
corresponding data are summarized in Suppl. Table 3. Mosaicism has been reported in 8 other independent 
families in which a point mutation or an intragenic rearrangement of SCN1A was identified [14, 34, 36, 
37, 41]. One additional case (Glu289X, inherited from the mother) was also probably due to mosaicism 
although this was not demonstrated [29]. Only one DS patient with an identified SCN1A mutation 
(Met1841Thr) within a large GEFS+ family [23] was reported. In all other patients (who all had missense 
mutations), parents were not tested or mosaicism was not ascertained [29, 30, 33, 42]. 
Somatic mosaicism was suspected in the families reported in this study since the amount of mutation in the 
parent appeared lower than that of his child with DS. In 3 families, however, the mutation could not be 
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detected by direct sequencing since its amount was less than 20% in DNA from blood cells. In these cases, 
the recurrent transmission of the mutation to another affected child prompted us to search for mosaicism. 
In absence of a second affected child, mosaicism in these families would have been missed. If we admit 
that the recurrent transmission of the mutation is weakly probable when mosaicism is low, then it is very 
likely that mosaicism could be more frequent than 7%. The risk of recurrence is, therefore, not null when 
the mutation is apparently de novo, which should be taken into account for genetic counseling. Somatic 
mosaicism could even turn out to be more frequent as originally suspected. Here, we have detected only 
mosaic parents who have transmitted the mutation to their offsprings. It is difficult to predict how many 
patients could have a SCN1A mutation at the somatic mosaic state without transmitting it. One could 
hypothesize that somatic mosaicism of SCN1A - or other genes - affecting the brain is one cause 
accounting for isolated patients with idiopathic epilepsies or febrile seizures. 
In this study, quantitative allele-specific amplification of the mutation in the blood of the mosaic parent 
revealed that the amount of the mutation was very variable for one parent to another (from 0 to 85%). The 
clinical status of the mosaic parent appeared somehow correlated with the amount of the mutation in his 
blood cells although this correlation is not strict. Indeed, the transmitting parents with the lowest 
percentages (<30%, families 10-12) of mutation were all unaffected. Three parents out of the 6 with a 
mutation rate close to 50% (families 3-8) were affected suggesting that in this case, the parent had a 50% 
risk of being affected. These observations suggest that the occurrence and severity of the epilepsy could be 
correlated with the amount of mutation in the brain of the parent although this hypothesis is difficult to 
demonstrate in absence of post-mortem tissues. Peripheral mosaicism does not always reflect the neuronal 
mosaicism as blood cells and neurons are not originated from the same embryonic stem cells. However, 
when the mutation occurs late during development, the probability that the mutation is present at a high 
rate in a tissue is weak. Conversely, when the mutation occurs very early in the development, the presence 
of the mutation in a tissue happens randomly or is dependent from negative selective pressure. If there is 
no selective pressure, and cells of the tissue originate from a population including many mutated cells, the 
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amount of mutation could be very high in most tissues [40, 43]. This would explain why we observed a 
partial correlation between the clinical status of the mosaic parent and the amount of mutation in his blood 
cells. Another interesting issue is that only specific neuron types could be sensitive to or affected by the 
mutation, as reported for the Arg1648His mutation [44]. In that case, the higher the amount of mutation is, 
the higher the probability that these neurons would express it.  
At least 30 other genetic diseases showing variable expressivity have been linked to somatic mosaicism 
[40, 43]. Most of these diseases are severe and it is likely that somatic mosaicism is more frequent in 
disorders with an elevated rate of de novo mutations. However, although case reports of mosaicism are 
frequent in such disorders, the consequences of mosaicism and the correlation between the amount of 
mutation in concerned tissues and the clinical variability are rarely studied. 
One question that remains is whether SCN1A neomutations (causing DS) act through the same 
pathophysiological mechanisms than mutations found in GEFS+. Both situations presented here give 
valuable insights regarding this issue. Basically, mutations associated with clear loss-of-function are 
almost always associated with DS and are never found in GEFS+. However, these mutations can be 
associated with milder phenotypes reminiscent of those seen in GEFS+ if present in only some neurons. 
Conversely, missense mutations found in GEFS+ are generally associated with mild epileptic phenotypes 
but can occasionally cause DS. From a mechanistic point of view, it is likely that the pathophysiological 
pathways are different: de novo mutations would be sufficient to cause DS whereas missense mutations 
associated with GEFS+ would not and additional genetic or non-genetic factors would be necessary to 
cause DS in the latter case. A recent study provides an interesting hypothesis regarding factors that could 
influence the disorder: mutations identified in GEFS+ families would result in folding-defective proteins 
which function could be partially rescued by interactions with associated proteins and drugs. In this 
context, severe phenotypes such as DS could emerge within a permissive genetic background [22, 45]. The 
example of family 12 shows that the limits between DS and GEFS+ are even more blurred that patients 
with truncating mutations could also present with milder phenotypes. In both cases, yet unidentified 
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factors obviously influence the course and outcome of the disease. Parental mosaicism having main 
consequences in terms of genetic counseling, it is thus important to recognize it when possible. A prenatal 
diagnosis should be achievable once the pathogenicity of the mutation has been determined. 
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 FIGURE LEGENDS 
 
Figure 1. Pedigrees and segregation analysis of the SCN1A mutations in families 1-19. A) Families 1-
13: Mutations found in DS patients were inherited from a mosaic asymptomatic or mildly affected 
parent; B) Families 14-19: Missense mutations found in DS patients segregated in families with 
autosomal dominant generalized epilepsy with febrile seizures plus (GEFS+) and were associated with 
variable expressivity. The arrow indicates the index case. Black symbols correspond to patients with 
Dravet syndrome (DS). Grey symbols represent patients with idiopathic generalized epilepsy (IGE). 
Right upper black squares indicate patients who had febrile seizures. Symbol with crosswise hatching 
stands for a patient with symptomatic epilepsy after head trauma.  
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Table 1A: DS patients with a SCN1A mutation inherited by a mosaic parent 
Family 
Nb of 
SMEI 
children 
Mutation type 
(Mutation) 
Transmission to 
the SMEI child 
Clinical status of 
transmitting 
parent 
% of mutated allele in parent’s blood cells 
(TaqMAMA quantification) 
Detection of the mutation in 
parent’s blood cells (direct 
sequencing) 
1 1 Truncating  (c.1378+1G>A) Paternal 
Severely Affected 
but not DS 85.18 ± 12 Yes 
2 1 Truncating  (c.3878delA) Paternal Affected 64.59 ± 10 Yes 
3 2 Truncating  (p.Arg542X) Maternal Unaffected 54.04 ± 4 Yes 
4 2 Truncating  (602+1G>A) Maternal Unaffected 50.06 ± 6 Yes 
5 1 Missense (p.Ile124Asn) Maternal 
Severely Affected 
but not DS 49.77 ± 5 Yes 
6 1 Truncating  (p.Arg712X) Maternal Unaffected 45.70 ± 7 Yes 
7 1 Missense (p.Asn191Tyr) Paternal Affected 45.33 ± 8 Yes 
8 1 Truncating  (c.5493delT) Maternal Affected 43.05± 7 Yes 
9 1 Missense (p.Ile1782Met) Paternal 
Affected (seizures 
after a head 
trauma) 
33.63 ± 5 Yes 
10 
1 (+ 1 child 
prematurely 
deceased) 
Truncating  
(p.Arg1912X) Paternal Unaffected 17.52 ± 1 No 
11 2 Truncating  (c.965-2A>C) Paternal Unaffected 6.05 ± 2 No 
12 1 Truncating (p.Arg580X) Maternal Unaffected 0.04 ± 0.01 No 
13 2 Whole gene deletion NA Unaffected 
NA 
 
NA 
 
NA: Not available; Nb: number 
 
 Table 1B: DS patients with a SCN1A mutation inherited in a GEFS+ familial context 
Family Nb of SMEI children Transmission to the SMEI child Clinical status of transmitting parent Mutation type (Mutation) 
23 
 
14 1 Paternal (de novo in the father) Affected Missense (p.Thr875Lys) 
15 1 Paternal (de novo in the father) Affected Missense (p.Asn1367Lys) 
16 1 Maternal (Familial) Affected Missense (p.Leu1514Ser) 
17 1  
Paternal  inheritance suspected 
(Familial) Unaffected 
Missense 
(p.Arg1648His) 
18 1 Maternal (Familial) Unaffected Missense (p.Thr1658Met) 
19 1 Maternal (Familial) FS Missense (p.Met1664Lys) 
NA: Not Available; Nb: number 
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